TY - JOUR ID - 3159 TI - Still the Great Debate – “Fair Balance” in Direct-to-Consumer Prescription Drug Advertising; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters” JO - International Journal of Health Policy and Management JA - IJHPM LA - en SN - AU - Rollins, Brent L. AD - School of Pharmacy, Philadelphia College of Osteopathic Medicine (PCOM), Suwanee, GA, USA Y1 - 2016 PY - 2016 VL - 5 IS - 4 SP - 287 EP - 288 KW - Food and Drug Administration (FDA) KW - Direct-to-Consumer Advertising (DTCA) KW - Notice of Violations (NOV) KW - Office of Prescription Drug Promotion (OPDP) KW - Fair Balance DO - 10.15171/ijhpm.2016.17 N2 - The above titled paper examined the Food and Drug Administration’s (FDA’s) warning letters and notice of violations (NOV) over a 10-year period. Findings from this content analysis reinforced what has been the primary issue for prescription direct-to-consumer advertising (DTCA) since its beginning, the fair balance of risk and benefit information. As opposed to another analysis in 2026 about this still being an issue, is there anything that can be done to prevent this problem from continuing? UR - https://www.ijhpm.com/article_3159.html L1 - https://www.ijhpm.com/article_3159_c3eba2a1569361b654b9856b57228c65.pdf ER -